Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,442 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,442 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | Phase 2 | withdrawn | Jul 19, 2019 | National Cancer Institute (NCI) | slow/insufficient accrual. | Enrollment / accrual |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | withdrawn | Aug 16, 2019 | M.D. Anderson Cancer Center | Study withdrawn by supporter | Other (stated, no rule matched) |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical… | Phase 4 | terminated | Jan 4, 2013 | Qidong Gaitianli Medicines Co., Ltd | difficult to recruit patients | Enrollment / accrual |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | — | terminated | Mar 2, 2009 | Baylor College of Medicine | Funding ended | Funding |
| NCT03079778 | Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy…(TACERT) | N/A | withdrawn | Mar 14, 2017 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Opened up a separate Clinicaltrials.gov trial form, study ID TACE | Other (stated, no rule matched) |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay… | Phase 2 | withdrawn | Oct 20, 2015 | Zhejiang University | no patients enrolled | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion… | Phase 3 | terminated | Aug 15, 2016 | Sun Yat-sen University | Midterm analysis showed negative results. | Other (stated, no rule matched) |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of… | Phase 2 | terminated | Apr 24, 2015 | US Oncology Research | insufficient accrual | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04125225 | What Are the Experiences of Patients With Pseudomyxoma Peritonei? | — | withdrawn | Oct 14, 2019 | University of Southampton | No participants enrolled. | Enrollment / accrual |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | Phase 2 | withdrawn | Oct 22, 2019 | Abramson Cancer Center at Penn Medicine | Halozyme halted development of PEGPH20 following Phase 3 failure. | Other (stated, no rule matched) |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | University Medical Center Groningen | Insufficient tumor-to-background ratios in the first three dose groups | Other (stated, no rule matched) |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | Phase 1 | withdrawn | Mar 7, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | We need to make significant adjustments to proposed drug and its delivery method | Other (stated, no rule matched) |
| NCT03943771 | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to…(R3DP-A) | N/A | withdrawn | May 9, 2019 | University Hospital, Bordeaux | Schedule issue | Other (stated, no rule matched) |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for… | Phase 1 / Phase 2 | terminated | Sep 12, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study was terminated due to cease in manufacturing of study drug. | Drug supply |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Phase 1 / Phase 2 | withdrawn | Aug 15, 2013 | Mirror Biologics, Inc. | interventional radiologist suffered stroke and unable to perform RFA procedure | Other (stated, no rule matched) |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Phase 1 / Phase 2 | withdrawn | Nov 26, 2013 | Mirror Biologics, Inc. | Study site change to Thailand | Other (stated, no rule matched) |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung… | Early Phase 1 | terminated | Oct 16, 2012 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver… | Phase 2 | withdrawn | Nov 13, 2014 | A2 Healthcare Taiwan Corporation | At sponsor's discretion | Other (stated, no rule matched) |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT02487277 | PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | Phase 2 | terminated | Jul 1, 2015 | Andrew Ko | Low accrual | Enrollment / accrual |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients… | Phase 2 | terminated | Jul 13, 2009 | Mayo Clinic | not stated | Not stated |
| NCT03692338 | INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or…(INTERVAL) | N/A | terminated | Oct 2, 2018 | Duke University | Poor accrual | Enrollment / accrual |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab +…(ATTILA) | Phase 3 | withdrawn | Jan 22, 2019 | iOMEDICO AG | Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP… | Other (stated, no rule matched) |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy… | Phase 1 / Phase 2 | terminated | Sep 11, 2009 | Celgene | MTD determined sub-optimal as efficacious treatment for renal cell carcinoma. | Other (stated, no rule matched) |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | N/A | terminated | Nov 1, 2013 | Yale University | Lack of patient enrollment | Enrollment / accrual |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure due to slow/insufficient accrual. | Enrollment / accrual |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | Phase 2 | terminated | May 2, 2008 | National Cancer Institute (NCI) | A more highly selected protocol with ESO TCR opened for pts with melanoma | Other (stated, no rule matched) |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With… | Phase 1 | withdrawn | Nov 11, 2014 | University of Hawaii | Closed due to no accrual | Enrollment / accrual |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment… | N/A | terminated | Dec 23, 2014 | Istituto Clinico Humanitas | too slow enrollment | Enrollment / accrual |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Phase 1 | terminated | Jun 10, 2016 | Virginia Commonwealth University | Study drug no longer being clinically developed by manufacturer | Drug supply |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | Phase 2 | terminated | Mar 7, 2012 | Novartis Pharmaceuticals | As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that… | Other (stated, no rule matched) |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With… | Phase 2 | terminated | Dec 3, 2010 | OHSU Knight Cancer Institute | low enrollment | Enrollment / accrual |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma… | Phase 1 / Phase 2 | terminated | May 19, 2015 | Fox Chase Cancer Center | IRB study closure facilitated by Investigator | Investigator |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | Phase 1 | withdrawn | Nov 13, 2018 | Lee's Pharmaceutical Limited | Sponsor's commercial decision | Other (stated, no rule matched) |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | Phase 3 | terminated | May 16, 2012 | SFJ Pharma Ltd. II | Primary endpoint did not reach statistical significance | Other (stated, no rule matched) |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in… | Phase 2 | terminated | Jul 3, 2013 | Women's Cancer Study Group GmbH | Early termination due to significant lack of relevant patient data for evaluation of objectives. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Mar 16, 2020source: clinicaltrials